As Pharma and biotech companies increasingly turn to contract development and manufacturing organizations (CDMOs) as extensions of their development and manufacturing departments, Avéma Pharma Solutions will be investing in both human capital and equipment to meet the demand. The full-service CDMO has announced plans to invest in new manufacturing equipment to produce solid-dose products, adding additional granulation and encapsulation suites, purchasing more analytical equipment, and adding headcount in R&D and manufacturing. The company also recently expanded its liquid manufacturing capabilities and added full on-site serialization capabilities to its packaging lines.
Avéma Pharma Solutions Announces Plans to Expand Miami R&D and Manufacturing Capabilities
Avéma Pharma Solutions is pleased to be attending CPhI in Philadelphia (May 17-19, Philadelphia Convention Center) at Booth #1315. We look forward to seeing our…Continue reading
Join Avéma Pharma Solutions at CPhI North America (August 10-12, Philadelphia Convention Center) at booth #1325. Attending the show on behalf of the company will…Continue reading
Avéma Pharma Solutions, a division of PL Developments (PLD), is in the unique position being both a consumer and supplier of global CDMO services for…Continue reading
On June 28, 2019 PL Developments, the parent company of Avema Contract Services, bought the U.S. store-brand, over-the-counter medicine division of Teva, which is headquartered…Continue reading
Westbury, NY – April 19, 2019 – Avéma Contract Services, a Contract Development Manufacturing Organization (CDMO) powered by PL Developments, will showcase its range of…Continue reading
Leave a reply